Literature DB >> 31681401

Consensus-Expressed CXCL8 and MMP9 Identified by Meta-Analyzed Perineural Invasion Gene Signature in Gastric Cancer Microarray Data.

Xiuzhi Jia1, Minjia Lu2, Chen Rui1, Ying Xiao1.   

Abstract

As an underrecognized route of cancer metastasis, perineural invasion (PNI) is defined as the neoplastic invasion of nerves, which can be targeted to inhibit the metastasis of malignant cancer. However, the mechanism underlying PNI in cancer is largely unknown. We constructed a PNI gene signature based on a Pathway Studio-mediated literature screen and investigated the relevant genes in a gastric cancer model. Thus, a total of 467 studies/datasets were retrieved from the Gene Expression Omnibus database using the keyword "gastric cancer," among which 13 studies that focused on gene expression profiling were further manually inspected and selected. Furthermore, the constructed PNI gene signature (104 genes) expression was meta-analyzed, and the consensus-expressed C-X-C motif chemokine ligand 8 (CXCL8) and matrix metallopeptidase 9 (MMP9) (p < 0.01, |log fold change| >1) were detected. Importantly, the disease-free survival was significantly worse in patients with high expressions of CXCL8 and MMP9 than in those with low expressions (p = 0.05). Moreover, multiple linear regression analysis showed that the population region (country) was associated with the expressions of both CXCL8 and MMP9. In conclusion, these data suggest that the coexpression of CXCL8 and MMP9 could be an early detection marker for PNI, with a potential to be utilized as individual therapy targets for early treatment to prevent PNI-related cancer metastasis.
Copyright © 2019 Jia, Lu, Rui and Xiao.

Entities:  

Keywords:  fixed-effects model; gene expression omnibus; gene expression profiling interactive analysis; random-effects model; the cancer genome atlas

Year:  2019        PMID: 31681401      PMCID: PMC6798046          DOI: 10.3389/fgene.2019.00851

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


Introduction

As a worldwide health concern owing to its metastasis and recurrence, gastric cancer is one of the most common malignant neoplasms and the second leading cause of cancer-relevant deaths (Sawaki et al., 2018; Khan and Shah, 2019; Necula et al., 2019). In China, patients are often diagnosed in the late stage, and the 5-year overall survival is less than 50% even after radical resection; most of the patients die of recurrence and metastasis (Riihimaki et al., 2016; Zong et al., 2016). It is worth noting that metastatic gastric cancer is a very serious and quickly spreading malignancy, which usually begins in the innermost mucus lining of the stomach, quickly invades deeper layers of muscle tissue, and metastasizes to the abdominal cavity, esophagus, intestines, liver, pancreas, and lymph nodes within several months. To reduce the risk of widespread metastasis and potentially fatal complications, early diagnosis and treatment are urgently recommended. For some tumors, perineural invasion (PNI) could be detected without vascular or lymphatic invasion and may be the sole route for the metastatic spread, which can cause local recurrence and distant metastasis (Liebig et al., 2009; Liu et al., 2012; Arese et al., 2018; Chen et al., 2019). Extensive prospective studies have shown that PNI is an independent prognostic factor affecting the outcome and survival of gastric cancer patients with curative resection, which is independent of the depth of invasion, tumor size, and lymph node status (Deng et al., 2014; Espana-Ferrufino et al., 2018). Thus, early detection of PNI might benefit the early diagnosis of cancer metastasis and treatment for malignant tumor. Despite the fact that a few detailed mechanisms are deciphered for PNI, little progress has been made to target PNI-related bioprocesses owing to the lack of proper methodologies. Gene expression profiling represents a high-throughput method of screening potential biomarkers and therapeutic targets to better understand PNI. In this study, the constructed PNI gene signature expression in gastric cancer is meta-analyzed, and the consensus expressions of C-X-C motif chemokine ligand 8 (CXCL8) and matrix metallopeptidase 9 (MMP9) are screened, indicating that a CXCL8/MMP9-relevant PNI process could be targeted to prevent further metastasis.

Materials and Methods

PNI Gene Signature Construction

The Pathway Studio database (Bonnet et al., 2009) (www.pathwaystudio.com) was utilized to screen the literature until April 2019, and the interactions containing biological gene–PNI relations were extracted to construct PNI gene signatures, all of which could provide extensive coverage and high-quality scientific evidence to investigate the potential functional genes associated with PNI.

Gene Annotation Analysis

The PNI gene signature was annotated with the Database for Annotation, Visualization and Integrated Discovery (DAVID; http://david.abcc.ncifcrf.gov/) (Huang et al., 2009a; Huang et al., 2009b) based on gene ontology (GO) terms such as biological process, molecular function, and cellular component, which were then iteratively examined by the Fisher exact test and false discovery rate. The annotated terms were further enriched with GOView (http://www.webgestalt.org/GOView), which could present the enrichment results of multiple GO terms under the GO Directed Acyclic Graph (DAG) structure (Wang et al., 2017).

Gene Expression Data Retrieved From Gene Expression Omnibus

A systematic search was conducted with expression datasets from Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) (Clough and Barrett, 2016). In total, 467 datasets/series were identified on the basis of the keyword “gastric cancer.” Thirteen of these 467 studies, which satisfied the selection criteria, were included in the meta-analysis, as shown in . As indicated in , expression data detected in different platforms were combined in the GSE37023 dataset, so the data analyzed in the different platforms were analyzed separately. The selection criteria were as follows: (1) the data type was expression profiling by array; (2) the overall design was gastric cancer case versus healthy control; (3) the sample size was greater than or equal to 20; (4) both the number of cases and control groups were greater than or equal to 5; and (5) the sample organism was Homo sapiens.
Table 1

Gastric cancer dataset employed for meta-analysis.

GEO IDContributorNo. ControlsNo. casesCountrySample organism
GSE19826Peng et al., 20101512ChinaHomo sapiens
GSE3438Kim et al., 20064950South KoreaHomo sapiens
GSE13861Cho et al., 20111965USAHomo sapiens
GSE13911De Rinaldis et al., 20083138ItalyHomo sapiens
GSE29272Wang et al., 2013134134USAHomo sapiens
GSE29998Holbrook et al., 20124950SingaporeHomo sapiens
GSE31811Kitamura et al., 20141721JapanHomo sapiens
GSE37023Wu et al., 2012 (GPL97)3629SingaporeHomo sapiens
GSE37023Wu et al., 2012 (GPL96)36112SingaporeHomo sapiens
GSE44740Varro et al., 20131212United KingdomHomo sapiens
GSE64951Yoshizawa et al., 20153163USAHomo sapiens
GSE79973Shao et al., 20161010ChinaHomo sapiens
GSE81948Sacconi et al., 2017515ItalyHomo sapiens
Gastric cancer dataset employed for meta-analysis.

Meta-Analysis Models

Both the fixed-effects model and random-effects model were utilized to study the effect size of the PNI gene signature in the cases of gastric cancer. The expression data were normalized and log2-transformed if these were not done in the original dataset. For each expression dataset, the log fold change (LFC) was calculated and used as the index of effect size in the meta-analysis. The heterogeneity of the meta-analysis was analyzed to indicate the variance within and between different studies. If the total variance Q was equal to or smaller than the expected between-study variance df, the statistic ISq = 100% × (Q − df)/Q would be set as 0, and a fixed-effects model was selected for the meta-analysis. Otherwise, a random-effects model was selected. The Q-p value represented the probability that the total variance was derived from the within-study variance only. Significant genes from this meta-analysis were reported, which were identified with the following criteria: p < 0.01 and effect size (LFC) >1 or <−1. When a gene presented an effect size (LFC) >1 or <−1 in the meta-analysis, it meant that the change of the expression was greater than twofold or smaller than 0.5-fold.

Gene Expression Profiling Interactive Analysis

As an interactive website based on The Cancer Genome Atlas (TCGA) project data, Gene Expression Profiling Interactive Analysis (GEPIA) RNA-seq data (http://gepia.cancerpku.cn/) (Tang et al., 2017) were extracted to obtain CXCL8 and MMP9 expressions in human stomach adenocarcinoma and adjacent healthy tissues. The Pearson correlation test was utilized to determine the relationship between the CXCL8 and MMP9 expressions, as indicated by transcripts per kilobase million. Moreover, GEPIA data were utilized to determine the effects of CXCL8 and MMP9 coexpression on disease-free survival.

Multiple Linear Regression Analysis

A multiple linear regression (MLR) analysis was employed to study the possible effects of sample size, population region, and study date on the gene expression change in disease. P values and 95% confidence intervals were reported for each of the factors. This analysis was carried out in Matrix Laboratory (MATLAB, R 2017a) with the “regress” statistical analysis package.

Results

Functional Annotation Analysis of PNI Gene Signature

The PNI gene signature was obtained and constructed on the basis of Pathway Studio analysis, and a total of 104 genes were found to be attributed to the PNI gene signature ( ). The PNI gene signature was annotated with DAVID, and the annotated GO terms were further enriched and presented with interactive DAG visualization. As depicted in , most of the enriched GO categories identified for the PNI gene signature were closely related to the function of “cell surface receptor signaling pathway,” “cell migration,” “negative regulation of apoptotic process,” and “neurogenesis,” which are the main bioprocesses involved in PNI. This analysis gave clues that the molecular pathways that participate in the mechanism of tumor cell migration and survival could be responsible for the initiation of PNI.
Figure 1

Enrichment of annotated GO terms under the GO Directed Acyclic Graph with PNI-related genes.

Enrichment of annotated GO terms under the GO Directed Acyclic Graph with PNI-related genes.

Differential Expressions of CXCL8 and MMP9

The expression of the PNI gene signature in 13 GEO datasets of gastric cancer was meta-analyzed, among which CXCL8 and MMP9 were significantly expressed (p < 0.01, LFC >1 or <−1). Heterogeneity analysis showed that there was no significant between-study variance for both CXCL8 and MMP9 (ISq = 0, p-Q = 0.96), and therefore, a fixed-effects model was selected. The effect sizes and relevant statistical parameters are presented in , and the 95% confidence interval and weights of each study are presented in . The higher expression levels of both CXCL8 and MMP9 in a gastric cancer sample were also confirmed in the TCGA data when compared with a normal sample ( ) analyzed with GEPIA (Tang et al., 2017), and it was further found that the correlation between CXCL8 and MMP9 expressions was R = 0.49 ( , p = 0). Importantly, the relative expressions of CXCL8 and MMP9 signatures (high or low coexpression) could significantly affect disease-free survival ( , p = 0.05). All these indicated that the CXCL8 and MMP9 coactivated bioprocess might be the consistent phenotype involved in PNI-related gastric cancer.
Table 2

Significant genes identified from meta-analysis.

Gene nameRandom-effects modelNo. studiesLFCpISq (%)p-Q
CXCL8NO101.641.70e−300.96
MMP9NO61.405.11e−300.96

p Value represents the probability that the fold change is equal to 0. ISq = 100% × (Q − df)/Q represents the percentage of between-variance over total variance; p-Q represents the probability that the variance is coming from within-study only. LFC, log fold change (the effect size).

Figure 2

Effect size, 95% confidence interval, and weights for the genes (A) CXCL8 and (B) MMP9 from the meta-analysis results. The bar plot on the right of each figure represents the normalized weights for each dataset/study, which ranged between 0 and 1; the brighter (green) the color, the larger the weight (labeled right next to the bar). The star (in red) and lines (in blue) on the left are the mean of effect size (log fold change) and 95% confidence interval (CI) of each dataset/study, respectively.

Figure 3

Plot of differential expressions of CXCL8 (A) and MMP9 (B) in human stomach adenocarcinoma (STAD) tissue (n = 408) compared with normal tissue (n = 32). *p < 0.05.

Figure 4

Correlation between CXCL8 and MMP9 expressions as indicated by transcripts per kilobase million (TPM) among human stomach adenocarcinoma (STAD) patients.

Figure 5

Effect of coexpression of CXCL8 and MMP9 on disease-free survival among gastric cancer patients. Log-rank test was performed to indicate the disease-free survival analysis based on CXCL8 and MMP9 gene-pair expressions. The Cox proportional hazard ratio (HR) and 95% confidence interval information indicated by the dotted line can be referred in the survival plot.

Significant genes identified from meta-analysis. p Value represents the probability that the fold change is equal to 0. ISq = 100% × (Q − df)/Q represents the percentage of between-variance over total variance; p-Q represents the probability that the variance is coming from within-study only. LFC, log fold change (the effect size). Effect size, 95% confidence interval, and weights for the genes (A) CXCL8 and (B) MMP9 from the meta-analysis results. The bar plot on the right of each figure represents the normalized weights for each dataset/study, which ranged between 0 and 1; the brighter (green) the color, the larger the weight (labeled right next to the bar). The star (in red) and lines (in blue) on the left are the mean of effect size (log fold change) and 95% confidence interval (CI) of each dataset/study, respectively. Plot of differential expressions of CXCL8 (A) and MMP9 (B) in human stomach adenocarcinoma (STAD) tissue (n = 408) compared with normal tissue (n = 32). *p < 0.05. Correlation between CXCL8 and MMP9 expressions as indicated by transcripts per kilobase million (TPM) among human stomach adenocarcinoma (STAD) patients. Effect of coexpression of CXCL8 and MMP9 on disease-free survival among gastric cancer patients. Log-rank test was performed to indicate the disease-free survival analysis based on CXCL8 and MMP9 gene-pair expressions. The Cox proportional hazard ratio (HR) and 95% confidence interval information indicated by the dotted line can be referred in the survival plot.

Population Region Contribution to the Differential Expressions of CXCL8
and MMP9

Multiple linear regression analysis showed that population region (country) was a significant factor influencing the expressions (fold change) of both CXCL8 and MMP9 (p = 1.44e−3 and 2.12e−4, respectively) as revealed in and , whereas sample size and study date did not show such effect. Although large prospective studies are needed to confirm such observation, the population-correlated expression pattern indicated the necessity of considering a population-based treatment strategy.
Table 3

Multiple linear regression analysis on sample size, population region, and study date.

Gene nameSample sizePopulation regionStudy date
CXCL80.301.44e−30.074
MMP90.532.12e−40.99
Multiple linear regression analysis on sample size, population region, and study date.

Discussion

Perineural invasion is considered to be one of the determining factors that affect local recurrence and metastasis after resection. For the first time, a PNI gene signature (104 genes) is constructed in this investigation by the text mining method. The consensus-expressed PNI gene signature (CXCL8 and MMP9) in gastric cancer is identified on the basis of meta-analyzed GEO datasets. Moreover, the expressions of CXCL8 and MMP9 are associated with population or country, and the coexpression of CXCL8 and MMP9 has an effect on patient survival. A high accident rate of aggressive prostate cancer has been reported in patients of African descent, which can be attributed to the population, presence of PNI, and higher Gleason scores of cancer (Nzioka et al., 2014). All these indicate that individual and racial-dependent therapies based on CXCL8 and MMP9 for early treatment can be potentially utilized to prevent PNI. In summary, such analysis framework can be utilized to decipher molecular targets that can be attributed to a certain bioprocess in PNI. As a multifunctional proinflammatory chemokine, CXCL8 is significantly upregulated in both the tumor and tumor-derived microenvironment and acts as a key regulator of proliferation, migration, angiogenesis, metastasis, and resistance to chemotherapeutics through binding with the high-affinity CXCR1 and CXCR2 G-protein–coupled receptors (Lee et al., 2013). CXCR2 is upregulated in dorsal horn neurons after spinal nerve ligation, traumatic brain injury, and inflammation stimulation, which contribute to the maintenance of pain (Zhang et al., 2013; Cao et al., 2016; Liang et al., 2017). CXCL8 could stimulate the production and release of MMP2 and MMP9 (Sparmann and Bar-Sagi, 2004; Mantovani et al., 2008), which suggests that the invasiveness and extracellular matrix remodeling process can be modulated in the presence of CXCL8. It is worth noting that CXCL8 is involved in directing organ-specific metastasis to regional lymph nodes and perineurons where CXCR2 is expressed. CXCL8 and MMP9 overexpression correlates with the poor prognosis of bladder cancer. High-grade tumors express significantly higher levels of MMP9 and CXCL8 than low-grade tumors (Reis et al., 2012). Furthermore, CXCR2 stimulation could promote bladder cancer cell migration and invasion by activating the PI3K/AKT-induced upregulation of MMP2/MMP9 (Gao et al., 2015). It is interesting to note that CXCR2 silencing could reduce the expression of MMP9 and phosphorylated Akt, which indicates that Akt-induced MMP9 expression and activation may be a canonical pathway related to CXCR2 (Wu et al., 2016). In this research, consensus-expressed CXCL8 and MMP9 are identified in gastric cancer, and a higher coexpression can predict poor disease-free survival. All these hint that CXCL8 may mediate the PNI and the relevant abdominal pain through binding with CXCR2 to further activate MMP9, which need further investigation. High levels of CXCL8 expression in tissue might correlate with the tumorigenicity, angiogenesis, and metastasis of tumors in numerous xenograft and orthotopic models (Waugh and Wilson, 2008). In humans, a high expression level in a tumor sample may be associated with poor prognosis as stratified by tumor stage and pathology classification (Eck et al., 2003; Li et al., 2015). Moreover, it is further shown that high levels of CXCL8 in serum are correlated with disease aggressiveness and an unfavorable initial response to chemotherapeutic drugs, such as camptothecin, 5-fluorouracil, oxaliplatin, and paclitaxel (Lee et al., 2007; Baj-Krzyworzeka et al., 2016). All these indicate that CXCL8 can be utilized as a prognostic and predictive cancer biomarker to indicate a more aggressive phenotype. Therefore, CXCL8 inhibition might be a novel therapeutic strategy in targeting the tumor and the associated microenvironment. It must be mentioned that CXCL8 can regulate the development and progression of gastric cancer in an inflammatory-chemotaxis–independent manner, although the CXCL8 target fails to explain the signaling effects of other CXC chemokines that emerged in some preclinical trials (Lee et al., 2013). Therefore, a targeted strategy based on receptor selectivity, such as the inhibition of CXCR2, is put forward to eliminate the redundant function of CXCL8 signaling. The present investigation also shows that the expressions of both CXCL8 and MMP9 are related to population region or country, and the coexpression patterns of CXCL8 and MMP9 will affect disease-free survival. All these indicate the necessity of individual and racial-dependent therapies to target the activated CXCL8/MMP9 pathway or PNI bioprocess-specific target strategy to prevent further PNI-related metastasis.

Conclusions

In this investigation, a novel analytical framework of gene signature based on gene expression profile meta-analysis is proposed. The consensus expressions of CXCL8 and MMP9 might be considered as novel PNI-related targets to define biomarker-based subgroup stratification and to prevent PNI-mediated early metastasis.

Data Availability

The datasets analyzed for this study can be found in the GEO datasets: GSE19826, GSE3438, GSE13861, GSE13911, GSE29272, GSE29998, GSE31811, GSE37023, GSE37023, GSE44740, GSE64951, GSE79973, GSE81948.

Author Contributions

XJ and YX designed the investigation. XJ, ML, and CR performed the bioinformatics and statistical analyses. XJ and ML drafted the manuscript. YX revised the manuscript critically. All authors reviewed and approved the final version of the manuscript.

Funding

This project was supported by the scientific research start-up funds for specially engaged employee of Sir Run Run Shaw Hospital (Ytp1902), the National Nature Science Foundation of China (81660708), and the Key Project of the Tibetan Medical Administration of Tibet (2017005).

Conflict of Interest Statement

Author ML was employed by company Hangzhou Beiwo Meditech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  31 in total

1.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 2.  Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer.

Authors:  Han Liu; Qingyong Ma; Qinhong Xu; Jianjun Lei; Xuqi Li; Zheng Wang; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 3.  Optimizing Therapies in the Perioperative Management of Gastric Cancer.

Authors:  Uqba Khan; Manish A Shah
Journal:  Curr Treat Options Oncol       Date:  2019-05-29

Review 4.  Tumor progression: the neuronal input.

Authors:  Marco Arese; Federico Bussolino; Margherita Pergolizzi; Laura Bizzozero; Davide Pascal
Journal:  Ann Transl Med       Date:  2018-03

Review 5.  Review of recent efforts to discover biomarkers for early detection, monitoring, prognosis, and prediction of treatment responses of patients with gastric cancer.

Authors:  Koichi Sawaki; Mitsuro Kanda; Yasuhiro Kodera
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2018-06-25       Impact factor: 3.869

6.  Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma.

Authors:  M Eck; B Schmausser; K Scheller; S Brändlein; H K Müller-Hermelink
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

Review 7.  Perineural invasion in cancer: a review of the literature.

Authors:  Catherine Liebig; Gustavo Ayala; Jonathan A Wilks; David H Berger; Daniel Albo
Journal:  Cancer       Date:  2009-08-01       Impact factor: 6.860

8.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis.

Authors:  Anke Sparmann; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2004-11       Impact factor: 31.743

9.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.

Authors:  Zefang Tang; Chenwei Li; Boxi Kang; Ge Gao; Cheng Li; Zemin Zhang
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

Review 10.  Recent advances in gastric cancer early diagnosis.

Authors:  Laura Necula; Lilia Matei; Denisa Dragu; Ana I Neagu; Cristina Mambet; Saviana Nedeianu; Coralia Bleotu; Carmen C Diaconu; Mihaela Chivu-Economescu
Journal:  World J Gastroenterol       Date:  2019-05-07       Impact factor: 5.742

View more
  6 in total

1.  A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma.

Authors:  Akira Ooki; Taroh Satoh; Kei Muro; Atsuo Takashima; Shigenori Kadowaki; Daisuke Sakai; Takashi Ichimura; Seiichiro Mitani; Toshihiro Kudo; Keisho Chin; Shigehisa Kitano; Dung Thai; Marianna Zavodovskaya; JieJane Liu; Narikazu Boku; Kensei Yamaguchi
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

2.  Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).

Authors:  Manish A Shah; Gyorgy Bodoky; Alexander Starodub; David Cunningham; Desmond Yip; Zev A Wainberg; Johanna Bendell; Dung Thai; Joyce He; Pankaj Bhargava; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2021-02-12       Impact factor: 44.544

3.  microRNA-193a-5p Suppresses the Migratory Ability of Human KATO III Gastric Cancer Cells through Inhibition of Vimentin and MMP-9.

Authors:  Amir Baghbanzadeh; Elham Baghbani; Khalil Hajiasgharzadeh; Saeed Noorolyai; Vahid Khaze; Behzad Mansoori; Masoud Shirmohamadi; Behzad Baradaran; Ahad Mokhtarzadeh
Journal:  Adv Pharm Bull       Date:  2020-10-19

4.  Targeting IL8 as a sequential therapy strategy to overcome chemotherapy resistance in advanced gastric cancer.

Authors:  Huning Jiang; Jiahua Cui; Hao Chu; Tingting Xu; Mengyan Xie; Xinming Jing; Jiali Xu; Jianwei Zhou; Yongqian Shu
Journal:  Cell Death Discov       Date:  2022-04-29

5.  Identification of novel hub genes associated with gastric cancer using integrated bioinformatics analysis.

Authors:  Xiao-Qing Lu; Jia-Qian Zhang; Sheng-Xiao Zhang; Jun Qiao; Meng-Ting Qiu; Xiang-Rong Liu; Xiao-Xia Chen; Chong Gao; Huan-Hu Zhang
Journal:  BMC Cancer       Date:  2021-06-14       Impact factor: 4.430

6.  Mechanism of Herb Pairs Astragalus mongholicus and Curcuma phaeocaulis Valeton in Treating Gastric Carcinoma: A Network Pharmacology Combines with Differential Analysis and Molecular Docking.

Authors:  Zixuan Wu; Xiyang Pan; Chaosheng Deng; Minjie Cai; Kai Yuan; Peidong Huang; Guoqi Shi
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-14       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.